ADC Developmentfrom Concept to Clinic

Antibody-drug conjugates (ADCs) represent a potent combination of monoclonal antibody specificity and powerful small molecule payloads, enabling targeted therapy while mitigating unwanted side effects. With a surge in FDA approvals and over 100 ADCs now in clinical development, the field has seen substantial growth. However, the development process remains intricate, demanding meticulous optimization of various factors such as linker chemistry, payload selection, conjugation strategies, DAR (drug-to-antibody ratio), stability, and antibody integrity.

The ADC journey commences with linker-payload synthesis and bioconjugation. Eurofins Discovery, a leading player in this domain, provides extensive expertise in designing and synthesizing diverse linker technologies. These include protease-sensitive, glycosidase-sensitive, pH-sensitive, PEGylated, branched, and shielding linkers.

Payloads, manufactured in specialized high-containment facilities, are handled with utmost care due to their highly potent nature. A multitude of conjugation options are available, allowing for the exploration of different designs and the generation of ADCs with tailored pharmacokinetic profiles, enhanced stability, and controlled DAR distributions.

After conjugation, ADCs undergo rigorous purification through various chromatography techniques. These methods effectively eliminate unconjugated antibodies, excess linker-payload materials, and aggregates, resulting in highly pure ADC preparations. This purification step is crucial for reliable downstream analyses and accurate assessment of ADC performance.

DAR analysis, performed using high-resolution liquid chromatography-mass spectrometry (LC-MS), confirms linker-payload incorporation, identifies individual DAR species, and offers detailed insights into ADC homogeneity. This critical information aids in optimizing product consistency, efficacy, safety, and manufacturability.

The final stage involves a comprehensive suite of biochemical, functional, and cytotoxicity assays. Data-driven assessments of binding, biological function, and therapeutic potential through in vitro and in vivo studies help identify the most promising ADC candidates for further advancement and development. Eurofins Discovery offers a fully integrated ADC development platform, covering every stage of the workflow from linker-payload design to analytical characterization and functional assessment.

Leveraging deep expertise in chemistry, biochemistry, and antibody optimization, Eurofins Discovery scientists aid in mitigating development risks, shortening timelines, and optimizing ADC safety, efficacy, and manufacturability.